Literature DB >> 3355793

Transient platelet and HLA antibody formation in multitransfused patients with malignancy.

K McGrath1, M Wolf, J Bishop, M Veale, H Ayberk, J Szer, I Cooper, M Whiteside.   

Abstract

Fifty-nine patients receiving platelet transfusions for bone marrow failure secondary to malignancy were screened at regular intervals for the presence of antibodies to human leucocyte (HLA) and platelet specific antigens. HLA antibodies occurred in 19 patients, 10 of whom also developed platelet specific antibodies. The HLA antibodies disappeared in 10 of 15 patients followed for periods of 2-14 months. In two patients this occurred whilst still receiving platelet transfusions. Antibody reappeared in only two of six patients subsequently transfused. Antibodies to platelet specific antigens were detected in 28 patients. They were transient, often appeared in association with infection, and in 50% of cases tested demonstrated autoantibody activity. There was no association with antibiotic drug therapy, or PFA/EDTA-dependent cryptantigens. Platelet recovery at 1 h or 20 h post transfusion was not significantly reduced in the presence of platelet specific antibodies. These findings have important implications for the selection of platelet donors for alloimmunized recipients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355793     DOI: 10.1111/j.1365-2141.1988.tb04212.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Hematological support of a cancer patient.

Authors:  J M Shear; G Rock
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

2.  Frequency of Platelet Crossmatch Positivity and Predictive Value for Poor Platelet Increment Among Paediatric Oncohaematology Patients in India.

Authors:  Simon Kingsley; Mary Purna Chacko; P Amal; Grace Rebekah; G Mathew Leni; Daniel Dolly
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-25       Impact factor: 0.900

3.  Identification of platelet refractoriness in oncohematologic patients.

Authors:  Aline Aparecida Ferreira; Roberto Zulli; Sheila Soares; Vagner de Castro; Helio Moraes-Souza
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India.

Authors:  Vijay Kumawat; Ratti Ram Sharma; Pankaj Malhotra; Neelam Marwaha
Journal:  Asian J Transfus Sci       Date:  2015 Jan-Jun

5.  Antibodies against human platelet alloantigens and human leucocyte antigen class 1 in Saudi Arabian multiparous women and multi-transfused patients.

Authors:  Sarah K Al-Ouda; Abdulmajeed A Al-Banyan; Farjah H Al-Gahtani; Abdel-Galil M Abdel-Gader; Lateefa O Al-Dakhil
Journal:  Saudi Med J       Date:  2015-06       Impact factor: 1.484

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.